Literature DB >> 17237146

Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome.

Qing-Cheng Yang1, Bing-Fang Zeng, Yang Dong, Zhong-Min Shi, Zhi-Ming Jiang, Jin Huang.   

Abstract

BACKGROUND: Hypoxia is a common feature of many solid cancers and linked to malignant transformation, metastases and treatment resistance. Hypoxia is known to induce hypoxia-inducible factor-1alpha (HIF-1alpha) expression. The aim of this study is to investigate the impact of overexpression of HIF-1alpha on prognosis and the relationship with clinicopathological characteristics in human osteosarcoma.
METHODS: Immunochemistry with digital image analysis was used to determine the HIF-1alpha protein expression in histologic sections from 39 treated patients.
RESULTS: According to our study, expression of HIF-1alpha protein were detected in 31 of 39 cases (79%), with signal concentrated primarily within the nuclei of tumor cell. In contrast, non-cancerous adjacent tissues showed no HIF-1alpha immunoreactivity. HIF-1alpha expression was significantly associated with surgical stage, percentage of dead cells and microvessel density (MVD). Surgical stage, percentage of dead cells and HIF-1alpha expression showed significant influence on overall survival (OS) and disease-free survival (DFS) in univariate analysis. In multivariate analysis, surgical stage (IIA versus IIB/III) and percentage of dead cells (<90% versus > or =90%) were significant for DFS and OS. Those patients with HIF-1alpha moderate/strong expression showed significantly shorter OS and DFS compared with HIF-1alpha negative/weak expression.
CONCLUSIONS: Overexpression of HIF-1alpha is predictive of a poor outcome and might be a novel therapeutic target in human osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237146     DOI: 10.1093/jjco/hyl137

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  29 in total

Review 1.  A central role for hypoxic signaling in cartilage, bone, and hematopoiesis.

Authors:  Erinn B Rankin; Amato J Giaccia; Ernestina Schipani
Journal:  Curr Osteoporos Rep       Date:  2011-06       Impact factor: 5.096

2.  Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma.

Authors:  Huanli Zhao; Yuhui Wu; Yang Chen; Hongmei Liu
Journal:  Int J Clin Oncol       Date:  2015-06-16       Impact factor: 3.402

Review 3.  Targeting hypoxic response for cancer therapy.

Authors:  Elisa Paolicchi; Federica Gemignani; Marija Krstic-Demonacos; Shoukat Dedhar; Luciano Mutti; Stefano Landi
Journal:  Oncotarget       Date:  2016-03-22

4.  Hypoxia-induced epithelial to mesenchymal transition in cancer.

Authors:  Robert Y Hapke; Scott M Haake
Journal:  Cancer Lett       Date:  2020-05-26       Impact factor: 8.679

5.  Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry.

Authors:  Yong Chen; Yun Yang; Zhanna Yuan; Chunmeng Wang; Yingqiang Shi
Journal:  Oncol Lett       Date:  2012-02-10       Impact factor: 2.967

Review 6.  Hypoxia, stem cells and bone tumor.

Authors:  Wen Zeng; Rong Wan; Yuehuan Zheng; Shree Ram Singh; Yiyong Wei
Journal:  Cancer Lett       Date:  2011-09-29       Impact factor: 8.679

7.  Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma?

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Taisuke Furuta; Koji Arihiro; Mitsuo Ochi
Journal:  Clin Orthop Relat Res       Date:  2014-09-06       Impact factor: 4.176

8.  Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Authors:  Jie Jin; Lihong Cao; Lijun Wang; Zhaoming Wang; Wei Ding; Liping Mao; Shanshan Suo; Zhengping Zhuang; Hongyan Tong
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

Review 9.  The role of hypoxia-inducible factors in tumorigenesis.

Authors:  E B Rankin; A J Giaccia
Journal:  Cell Death Differ       Date:  2008-02-15       Impact factor: 15.828

10.  HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs.

Authors:  Carolyn Culver; Andrew Melvin; Sharon Mudie; Sonia Rocha
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.